Buying Thermo Fisher Scientific (TMO)? Here's What You Must Know.

Large-cap Industrials company Thermo Fisher Scientific has logged a 0.1% change today on a trading volume of 1,219,795. The average volume for the stock is 1,824,822.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. Based in Waltham, United States the company has 130,000 full time employees and a market cap of $191,690,735,616. Thermo Fisher Scientific currently offers its equity investors a dividend that yields 0.3% per year.

The company is now trading -5.52% away from its average analyst target price of $525.14 per share. The 23 analysts following the stock have set target prices ranging from $435.0 to $635.0, and on average give Thermo Fisher Scientific a rating of buy.

Over the last 12 months TMO shares have declined by -12.0%, which represents a difference of -26.0% when compared to the S&P 500. The stock's 52 week high is $609.85 per share and its 52 week low is $415.6. Based on Thermo Fisher Scientific's average net margin growth of 2.2% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 43,421,000 5,941,000 14 -6.67
2022 44,915,000 6,960,000 15 -25.0
2021 39,211,000 7,728,000 20 0.0
2020 32,218,000 6,375,000 20 42.86
2019 25,542,000 3,696,000 14 16.67
2018 24,358,000 2,938,000 12
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.